Coronavirus Notebook: EMA Begins Assessing AZ’s Evusheld, Apeiron Starts Phase I Trial Of Inhaled APN01
Executive Summary
The UK has explained its strategy for administering COVID-19 vaccines to people who have been partially immunized abroad.
You may also be interested in...
Janssen’s BCMA-Targeting CAR-T, AstraZeneca’s Evusheld Among EU Verdict Hopefuls
The EMA is poised to say whether or not six new drugs are on track for pan-EU approval, including Janssen’s first cell therapy and an antibody combination to prevent COVID-19 in people with poor immune response.
Biocon Buoyant On ‘Unique Positioning’ Of Partnered COVID-19 Antibody
Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.
Coronavirus Notebook: CEPI Calls For Reduced-Dose Booster Trials, Regeneron’s Ronapreve Filed In EU
EU health ministers are discussing booster and additional vaccines as well as COVID-19-related medicines shortages, and England is to offer approved vaccines to clinical trialists to ease international travel.